EcoDrugPlus

Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1-Like

Ensembl ID : ENSPKIG00000000726
Gene Symbol: LOC111860667
3 Cross references
147 Possible Orthologues:

Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta

Ensembl ID : ENSPKIG00000001536
Gene Symbol: IKBKB
3 Cross references
199 Possible Orthologues:

Inosine Monophosphate Dehydrogenase 1

Ensembl ID : ENSPKIG00000023359
Gene Symbol: IMPDH1
4 Cross references
330 Possible Orthologues:

Inosine Monophosphate Dehydrogenase 1

Ensembl ID : ENSPKIG00000008731
Gene Symbol: IMPDH1
2 Cross references
330 Possible Orthologues:

Inosine Monophosphate Dehydrogenase 2

Ensembl ID : ENSPKIG00000013837
Gene Symbol: IMPDH2
4 Cross references
200 Possible Orthologues:

Inositol Polyphosphate-5-Phosphatase D

Ensembl ID : ENSPKIG00000025393
Gene Symbol: INPP5D
1 Cross references
215 Possible Orthologues:

Insulin Like Growth Factor 1 Receptor

Ensembl ID : ENSPKIG00000013566
Gene Symbol: IGF1R
3 Cross references
271 Possible Orthologues:

Insulin Receptor

Ensembl ID : ENSPKIG00000010986
Gene Symbol: INSR
3 Cross references
212 Possible Orthologues:

Insulin Receptor-Like

Ensembl ID : ENSPKIG00000000920
Gene Symbol: LOC111847562
2 Cross references
213 Possible Orthologues:

Insulin-Like Growth Factor 1 Receptor

Ensembl ID : ENSPKIG00000020414
Gene Symbol: LOC111845734
2 Cross references
271 Possible Orthologues:

Integrin Alpha-Iib-Like

Ensembl ID : ENSPKIG00000018496
Gene Symbol: LOC111855947
3 Cross references
190 Possible Orthologues:

Integrin Beta-3-Like

Ensembl ID : ENSPKIG00000021012
Gene Symbol: LOC111856058
3 Cross references
201 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).